Mechanism of Action
Follistatin-344 acts by sequestering myostatin and activins, preventing them from binding their receptors.
Myostatin (GDF-8) Neutralization
Myostatin is a TGF-beta family member that binds ActRII receptors on myocytes and satellite cells, activating SMAD2/3 signaling to suppress muscle protein synthesis and inhibit satellite cell differentiation. One molecule of follistatin-344 binds two myostatin molecules simultaneously with sub-nanomolar affinity, removing myostatin from circulation and interstitial fluid. This releases the brake on skeletal muscle growth.[1]Activin A and B Inhibition
Follistatin-344 also neutralizes activin A and activin B, which share ActRII signaling with myostatin. Activin inhibition reduces muscle catabolism, reduces adipogenesis, and in some contexts reduces cancer-associated cachexia. This broader TGF-beta superfamily antagonism contributes to net anabolic and anti-catabolic effects.[2]Satellite Cell Activation
Without myostatin inhibition, satellite cells remain quiescent after normal muscle use. Follistatin-344 permits satellite cell activation and differentiation, enabling addition of new myonuclei to muscle fibers, the substrate of genuine hyperplasia that exceeds what is achievable through training alone.[1]Research Overview
Gene Therapy Phase I (Muscular Dystrophy)
Phase I ClinicalA 2015 Phase I trial injected follistatin gene (AAV1-FS344) into biceps of Becker muscular dystrophy patients. Six-minute walk test improved significantly; biopsies showed increased muscle fiber size and satellite cell number. Muscle mass gains of 15.5% persisted at 2-year follow-up, demonstrating durability of follistatin-driven muscle augmentation.[1]
Recombinant Protein Muscle Effects
Strong EvidenceSystemic administration of recombinant follistatin protein in mice and primates produces dramatic muscle mass increases (25-60% in mice at high doses). Single-injection intramuscular studies in monkeys showed 15-20% regional muscle hypertrophy. These effects are dose-dependent and reversed on discontinuation of protein therapy.[2]
Sarcopenia and Aging
Moderate EvidenceMyostatin levels increase with aging while follistatin levels decline, creating an imbalance that contributes to age-related muscle loss. Follistatin supplementation reverses muscle atrophy in aged rodent models. Clinical evaluation in sarcopenia is ongoing.[3]
Calculate your Follistatin-344 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Muscle augmentation | 100 µg | Once daily × 10–30 days | Subcutaneous or intramuscular |
| Anti-catabolic | 50–100 µg | Once daily | Subcutaneous |
Short research cycles (10-30 days) reflect the protein form's use model. Much of the clinical evidence is from gene therapy (single injection, permanent effect) rather than repeated protein injection. Purity and source quality are critical, follistatin protein is challenging to manufacture.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
Follistatin-344 safety profile is limited to Phase I gene therapy and preclinical protein studies.
WADA: Prohibited as a peptide hormone, growth factor, and gene doping agent.
Gene therapy risk: AAV-mediated gene therapy carries inherent risks (immunogenicity, insertional mutagenesis, off-target expression). Not applicable to recombinant protein administration.
Reproductive effects: Follistatin regulates activin in the reproductive system. High systemic levels may interfere with FSH regulation, ovarian function, and spermatogenesis. Cycle-based protocols reduce this risk.
Protein quality: Recombinant follistatin-344 purity and glycosylation pattern affect potency and immunogenicity. Research-grade quality varies significantly between suppliers.
Not FDA approved: Experimental compound. Phase I gene therapy data only.
References
- [1]Mendell JR, et al. "Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes." Mol Ther. 2015;23(5):870-879.
- [2]Lee SJ, et al. "Targeting myostatin and related TGF-beta family members for the treatment of muscle loss." FEBS J. 2020;287(19):4070-4093.
- [3]Zhu J, et al. "Follistatin-344 therapy improves muscle function in a mouse model of sarcopenia." Aging Cell. 2022;21(4):e13601.